An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones - Concepedia

Concepedia

Publication | Open Access

An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones

DOI Full Paper Access

44

Citations

25

References

2021

Year

Maria J. G. T. Vehreschild, Annie Ducher, Thomas Louie, Oliver A. Cornely, Céline Féger, Aaron Dane, Marina Varastet, Fabien Vitry, Jean de Gunzburg, Antoine Andremont,

Journal of Antimicrobial Chemotherapy

Abstract

In FQ-treated hospitalized patients, DAV132 was well tolerated, and FQ plasma concentrations unaffected. DAV132 preserved intestinal microbiota diversity and C. difficile colonization resistance.

References

	Year	Citations

Page 1